LINC00299 Antibody, Biotin conjugated

Applications in Research

The biotin-conjugated LINC00299 antibody is primarily validated for enzyme-linked immunosorbent assay (ELISA) . Its biotin tag facilitates binding to streptavidin-linked enzymes (e.g., HRP or alkaline phosphatase) or fluorophores, enabling signal amplification in assays. Potential applications include:

• Protein localization studies via streptavidin-mediated imaging.

• Quantitative detection of LINC00299-encoded protein in biological samples.

• Integration into multiplex assay systems using biotin-streptavidin interaction .

Validation and Quality Control

• Specificity: Produced using recombinant human LINC00299 protein (2-105AA) .

• Cross-reactivity: No reported cross-reactivity with non-target proteins in human samples .

• Performance: Demonstrated reactivity in ELISA; other applications (e.g., Western blot, IHC) require user validation .

Biotin Interference in Assays

High endogenous biotin levels (e.g., in egg yolk or serum samples) may compete with the conjugated antibody, leading to false-negative results. For such samples, consider:

• Using biotin-blocking agents prior to assay setup .

• Validating results with a non-biotin-dependent detection system .

Optimization Tips

• Antibody Dilution: Start with a 1:200 dilution in PBS or assay buffer .

• Signal Amplification: Pair with streptavidin-HRP or fluorescent streptavidin conjugates (e.g., Alexa Fluor®) .

Comparative Analysis of Available Conjugates

Source:

Research Findings and Limitations

• Sensitivity: Biotin conjugation enhances detection limits in ELISA by 10–100× compared to unconjugated antibodies .

• Limitation: Lack of validation in non-ELISA applications (e.g., Western blot, IHC) necessitates user-specific optimization .

• A 2023 study highlighted that biotinylated antibodies may yield unreliable results in samples with endogenous biotin >10 nM, emphasizing the need for stringent controls .